Tirzepatide vs semaglutide weight loss is one of the most common questions people bring to their doctors right now. Both medicines are used for chronic weight management, both are given as weekly injections, and both come with serious safety information. Yet they are not the same drug, and they do not have the same approved uses.
This guide compares the two in plain language. You will see what each medicine is, how the brand names fit together, and what the FDA has approved each one for. Zepbound contains tirzepatide. Wegovy contains semaglutide. Mounjaro and Ozempic contain the same active drugs but are labeled for type 2 diabetes.
You will also learn about the side effects people most often report, which are mainly stomach and gut problems. We cover the boxed warning about thyroid tumors that appears on both labels, and who should not use either medicine. We explain who may be eligible based on the label, and who should talk with a clinician before starting.
The trial record is covered in general terms. Studies of both medicines show meaningful weight loss on average, and tirzepatide has shown larger average weight loss in a head-to-head trial. But averages hide wide differences from person to person. The best choice depends on your health history, other medicines, side effects, cost, and coverage.
What Are Tirzepatide and Semaglutide?
Tirzepatide and semaglutide are prescription medicines that copy gut hormones involved in appetite and blood sugar. The brands covered in this guide are given as weekly injections. They work alongside a reduced-calorie diet and more physical activity, not instead of them.
Semaglutide is a GLP-1 receptor agonist. It imitates a hormone your gut releases after eating. Tirzepatide imitates that same hormone and a second one called GIP. This is why tirzepatide is often described as a dual GIP and GLP-1 medicine.
Both drugs slow how fast the stomach empties, help you feel full sooner, and reduce hunger signals in the brain. These shared effects explain why the tirzepatide vs semaglutide weight loss comparison comes up so often. They look similar from the outside, but the details differ.
The Brand Names, Sorted Out
The confusion usually starts with the names. Each active drug is sold under more than one brand, and the brand decides what the label covers.
- Zepbound: tirzepatide, labeled for weight management and, in some adults, sleep apnea.
- Mounjaro: tirzepatide, labeled for type 2 diabetes.
- Wegovy: semaglutide, labeled for weight management and certain heart and liver uses.
- Ozempic: semaglutide, labeled for type 2 diabetes.
- Rybelsus: semaglutide tablets, labeled for type 2 diabetes.
So when someone says “tirzepatide vs semaglutide,” they may be talking about the active drugs, the weight-loss brands, or the diabetes brands. It helps to be clear which one you mean when you talk to your prescriber.
Why the Brand Matters
A prescriber chooses a brand based on the condition being treated, the label, and what your insurance covers. A diabetes-labeled brand and a weight-labeled brand can contain the same drug, but the approved uses are not identical. If you are unsure which product you have been offered, ask your pharmacist or prescriber to explain the label.
Tirzepatide vs Semaglutide Weight Loss: Approved Uses (Zepbound vs Wegovy)
Zepbound and Wegovy are both approved for chronic weight management in adults, but their other approved uses differ. These differences are the clearest, most factual part of the tirzepatide vs semaglutide weight loss comparison, because they come straight from the FDA labels.
Both products appear in NIDDK’s list of FDA-approved weight-loss medications, which covers prescription options for long-term weight management. Here is how their labeled uses compare in general terms.
| Labeled use | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Chronic weight management in adults | Yes: obesity, or overweight with a weight-related condition | Yes: obesity, or overweight with a weight-related condition |
| Children and teens | Not labeled | Labeled for ages 12 and older with obesity |
| Heart attack and stroke risk | Not labeled | Labeled for adults with heart disease and obesity or overweight |
| Obstructive sleep apnea | Labeled for moderate to severe, in adults with obesity | Not labeled |
| Fatty liver disease with scarring (MASH) | Not labeled | Labeled for adults with moderate to advanced liver scarring |
Labels change as new studies are reviewed and approved. Treat this table as a starting point, then check the current prescribing information for each product.
What “Labeled” Means
An approved use, also called an indication, is a condition the FDA has reviewed evidence for and agreed the medicine can treat. A use that is not on the label is not automatically unsafe, but it has not gone through the same review for that purpose.
What About Mounjaro and Ozempic?
Mounjaro and Ozempic are labeled for type 2 diabetes, not for weight loss. They share their active drugs with Zepbound and Wegovy. Many people lose weight on them, but the weight-loss label belongs to the other two brands. Which product you should use is a decision to make with your prescriber, based on your health conditions and your coverage.
Tirzepatide vs Semaglutide Weight Loss in Clinical Trials
Both medicines were tested in large trials, and both helped people lose more weight than a placebo. The trial programs have different names. Tirzepatide’s weight-management program is called SURMOUNT. Semaglutide’s is called STEP.
What the Main Trials Showed
In the first large SURMOUNT trial, adults with obesity or overweight and no diabetes lost about 21% of their body weight on average at the highest studied dose after 72 weeks. In the first large STEP trial, a similar group lost about 15% on average after 68 weeks. In both trials, people taking a placebo lost only a few percent.
These numbers come from separate studies with different people and different designs, so they cannot be compared directly.
The Head-to-Head Trial
A later trial called SURMOUNT-5 compared the two medicines directly in adults with obesity and no diabetes. Tirzepatide produced larger average weight loss than semaglutide over 72 weeks, roughly 20% versus 14% of body weight. Direct comparisons like this one are the most useful kind of evidence for the tirzepatide vs semaglutide weight loss question.
How to Read These Numbers
Averages are only a starting point. Keep these points in mind:
- Individual results vary. Some people lose much more than the average, and some lose much less.
- People with type 2 diabetes tend to lose less weight on average than people without diabetes.
- Trial participants got lifestyle support. Results in daily life may differ.
- Weight often returns after stopping. These medicines treat a long-term condition, and stopping them commonly leads to regained weight.
- More weight loss is not always the better goal. Side effects, cost, and your other health conditions matter too.
A clinician can explain what the trial results may mean for your own situation and what outcomes are realistic.
Side Effects: What to Know About GI Adverse Effects
The most common side effects of both medicines affect the stomach and gut. Doctors call these gastrointestinal adverse effects, or GI AEs. They are similar for tirzepatide and semaglutide, so they rarely settle the tirzepatide vs semaglutide weight loss question on their own.
Common GI Side Effects
People most often report:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach pain or bloating
- Heartburn, burping, or reflux
Most of these are mild to moderate. They tend to show up when treatment starts or when the amount of medicine is increased, and they often ease with time. Some people still have them for longer, and a few stop treatment because of them.
Why They Happen
These medicines slow how quickly food leaves the stomach. They also act on appetite and nausea centers in the brain. Food sits longer, you feel full sooner, and for some people that comes with queasiness, gas, or changes in bowel habits.
Habits That May Help
Your prescriber or pharmacist may suggest simple changes. Examples include:
- Eating smaller meals and stopping when you feel full
- Eating slowly
- Limiting greasy, fried, or very rich foods
- Drinking fluids through the day
- Talking with your prescriber about constipation early, before it becomes severe
These tips are general. They do not replace advice from your own care team.
When to Call a Clinician or Get Urgent Care
GI symptoms can sometimes point to a serious problem. The labels for both medicines warn about pancreatitis, gallbladder problems, and dehydration that can harm the kidneys. Contact a clinician promptly if you have:
- Severe or lasting stomach pain, with or without vomiting
- Pain in the upper right belly, fever, or yellowing of the skin or eyes
- Vomiting or diarrhea that will not stop
- Signs of dehydration, such as dizziness, very dark urine, or passing little urine
Get emergency help right away for swelling of the face, lips, or throat, trouble breathing, or severe allergic symptoms.
Boxed Warnings and Other Safety Points
A boxed warning is the strongest warning the FDA puts on a drug label. Both Zepbound and Wegovy carry one, and it is the same in both: a risk of thyroid C-cell tumors.
The Thyroid C-Cell Tumor Warning
In studies in rodents, these medicines caused thyroid C-cell tumors, including cancers. It is not known whether they cause these tumors, including a rare cancer called medullary thyroid carcinoma, in people. Because of this uncertainty, the warning is on the label.
People are told to report symptoms such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.
Who Should Not Use These Medicines
Neither medicine should be used by people who:
- Have a personal or family history of medullary thyroid carcinoma
- Have a rare genetic condition called multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Have had a serious allergic reaction to the medicine or its ingredients
Be sure your prescriber knows your full personal and family history before you start. This matters for both drugs equally, so it does not change the tirzepatide vs semaglutide weight loss decision between them.
Other Warnings on the Labels
Beyond the boxed warning, the labels list other risks. Common examples include:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems, including gallstones
- Dehydration and kidney injury, often after vomiting or diarrhea
- Low blood sugar, especially in people who also take insulin or certain diabetes pills
- Changes in vision in people with diabetic eye disease
- Mood changes and thoughts of suicide, which the labels advise watching for
- Slowed stomach emptying that can matter during procedures with anesthesia
For the details that apply to semaglutide products, see the FDA safety information on semaglutide medicines. The current full label for each product is the best place to check the complete list.
If you notice a worrying symptom, contact your clinician. If you think you may be in danger or are having thoughts of harming yourself, call 988 in the US or your local emergency number.
Who Is Eligible for Zepbound or Wegovy?
Eligibility starts with the label, and then moves to your own medical picture. A prescriber makes the final call. This section describes the general rules, not a personal recommendation.
The General Label Criteria
For chronic weight management in adults, both Zepbound and Wegovy are labeled for people who have:
- Obesity, which means a body mass index (BMI) of 30 or higher, or
- Overweight, a BMI of 27 or higher, plus at least one weight-related condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
BMI is a screening tool, not a full picture of health. Your clinician may also consider waist size, other conditions, and your history with diet and activity.
Wegovy is also labeled for teens 12 and older with obesity. Zepbound is labeled for adults. Other uses, such as sleep apnea for Zepbound or heart and liver conditions for Wegovy, have their own criteria on each label.
Both medicines are meant to be used with a reduced-calorie diet and more physical activity. For general background on prescription options, the MedlinePlus patient drug information pages explain what to expect in plain language.
Talk With a Clinician First If You
Some people need extra care, or may be told to avoid these medicines. Raise these points before starting:
- Are pregnant, planning a pregnancy, or breastfeeding. These medicines are not recommended during pregnancy, and your prescriber can advise on timing.
- Take birth control pills. Tirzepatide may make oral birth control less effective, so ask whether you need a backup method.
- Have had pancreatitis or gallbladder disease.
- Have kidney problems, or are prone to dehydration.
- Have diabetes, especially if you use insulin or similar medicines, because low blood sugar is possible.
- Have diabetic eye disease.
- Have severe stomach or digestive problems.
- Have a history of depression or thoughts of self-harm.
- Take other medicines or supplements. Slowed digestion can change how some oral medicines are absorbed.
Even if you meet the label criteria, you may not be the right candidate. And even if you fall just short of them, other effective options may exist. Your care team can walk through both.
GLP-1 Medicines Before Surgery: No One-Size Rule
If you have a procedure coming up, tell your surgical team about your medicine early. This applies to both tirzepatide and semaglutide products, and it is one reason the tirzepatide vs semaglutide weight loss choice should be made with a full medical team in mind.
Why Surgery Is a Special Case
These medicines slow stomach emptying. If food or liquid stays in the stomach when you are put under anesthesia or deep sedation, it can come up into the airway. This is called aspiration, and it can cause serious lung problems. The labels mention this risk, which is why anesthesia teams ask about these medicines.
There Is No Single Stop-or-Start Rule
Advice on whether to pause a dose, and for how long, has varied between medical groups and has changed as evidence has grown. The right plan can depend on:
- The type of procedure and the kind of anesthesia or sedation
- Which medicine you take, and the timing of your last dose
- Whether you are in the early weeks of treatment or have had a recent dose increase
- Whether you have nausea, vomiting, or bloating at the moment
- Your other health conditions, including diabetes
So this guide does not give a skip or restart schedule. Stopping on your own can also have downsides, such as higher blood sugar in people with diabetes.
What to Do Instead
- Tell your surgeon, anesthesiologist, and prescriber that you take the medicine, including the brand and the day of your last dose.
- Ask what instructions they want you to follow in the days before the procedure.
- Follow their fasting and diet directions exactly, since they may differ from the usual ones.
- Report any current stomach symptoms, such as nausea or fullness.
- Do not change or skip doses until your care team has told you what to do.
The same advice applies to scopes and other procedures that use sedation, not only to major surgery.
Compounded Versions, Cost, and Supply
Public interest in these medicines is high. You can see it in Google Trends data on tirzepatide vs semaglutide searches. With that attention comes a lot of marketing, so a few safety points are worth stating clearly.
Compounded Products Are Not the Same
Zepbound and Wegovy are FDA-approved products. Their strength, quality, and labeling have been reviewed. Compounded or “lookalike” versions sold online or in clinics are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality in the same way.
Some products sold online are labeled for research only or are sold with no prescription. These are not meant for people and can be unsafe. If you are offered a product that is not an FDA-approved brand, ask your prescriber and pharmacist why, and what the risks are.
Cost and Insurance
This article does not quote prices, because they change and vary by pharmacy and plan. A few general points hold true:
- Coverage differs a lot. Some plans cover these medicines for diabetes but not for weight management, and some require prior approval.
- The brand matters. Coverage may depend on which product the label supports for your condition.
- Ask your insurer what is covered, what paperwork is needed, and whether there are limits on how long coverage lasts.
- Ask your pharmacist about manufacturer savings programs, and read their terms carefully.
Supply
Availability of specific products and strengths can change over time. If your pharmacy cannot fill a prescription, do not switch to an unapproved source. Ask your prescriber about options instead.
If cost or supply is a worry, say so. Your care team can often suggest an approach that fits your budget and health needs.
Tirzepatide vs Semaglutide Weight Loss: Questions for Your Prescriber
There is no single winner for everyone. The better fit depends on your health, your goals, and practical limits. Here are the main trade-offs, based on the evidence covered above.
- Average weight loss. In a head-to-head trial, tirzepatide produced larger average weight loss than semaglutide.
- Other labeled uses. Zepbound has a sleep apnea indication. Wegovy has heart-risk and liver-disease indications, and can be used by teens 12 and older.
- Side effects. GI effects are common with both. Individual tolerance varies.
- Safety warnings. Both carry the same boxed warning about thyroid tumors.
- Practical factors. Insurance coverage, supply, and cost often shape the choice.
Questions Worth Asking
Bring a short list to your appointment. These can help:
- Am I a good candidate based on my BMI, health conditions, and history?
- Which approved product fits my needs, and why?
- Do I have any condition on the label that makes either medicine a poor choice?
- What side effects should I expect, and when should I call you?
- How does this interact with my other medicines, including birth control?
- What happens if I miss a dose, and who do I contact with questions?
- How will we track progress, and what are the goals beyond the scale?
- What eating and activity support will go along with the medicine?
- How long might I take it, and what is the plan if I stop?
- What will it cost, and does my insurance cover it?
Writing down the answers helps you remember them later. If something is unclear, ask your pharmacist as well.
Frequently Asked Questions
Which is better for weight loss, tirzepatide or semaglutide?
On average, tirzepatide led to more weight loss than semaglutide in a head-to-head trial. But the better medicine for you depends on your health history, side effects, other labeled uses, and coverage. Your prescriber can help you weigh them.
Are Zepbound and Mounjaro the same medicine?
They contain the same active drug, tirzepatide, but they are labeled for different conditions. Zepbound is labeled for weight management and sleep apnea in certain adults. Mounjaro is labeled for type 2 diabetes. The same is true of Wegovy and Ozempic for semaglutide.
Do both medicines have the same boxed warning?
Yes. Both carry a boxed warning about the risk of thyroid C-cell tumors. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2.
Can I take tirzepatide and semaglutide together?
They are not meant to be combined. Both act on the GLP-1 pathway, and the labels advise against using them with other medicines of this kind. Ask your prescriber before taking more than one.
Will I regain weight if I stop?
Many people do. Obesity is a long-term condition, and studies show that weight often returns after treatment ends. Talk with your prescriber about a long-term plan before starting.
Should I stop my medicine before surgery?
Do not decide this on your own. There is no single rule that fits everyone. Tell your surgeon and anesthesiologist that you take the medicine and follow their instructions.
Conclusion: Making Sense of Tirzepatide vs Semaglutide Weight Loss
The tirzepatide vs semaglutide weight loss question has no one-size answer. Both medicines are FDA-approved for chronic weight management in adults, both help many people lose meaningful weight, and both carry real safety warnings, including the boxed warning about thyroid tumors.
The differences are in the details. Tirzepatide showed larger average weight loss in a head-to-head trial, and Zepbound has a sleep apnea label. Semaglutide, as Wegovy, has heart-risk and liver labels and can be used by teens 12 and older. Side effects, cost, and coverage often decide what is practical.
The best next step is simple. Bring your questions to a licensed clinician, share your full health history, and make the choice together. Stay with FDA-approved products, and ask about surgery and pregnancy plans early.
Label date-stamp: Information reflects labeling as of October 12, 2026. Drug labels change, so check the current FDA label and ask your clinician or pharmacist.
Educational note: This article is for education only. It is not medical advice and is not a substitute for care from a licensed clinician. If you feel unsafe or are in crisis, call or text 988 in the US, or contact your local emergency number.
